THIS UNIT PURCHASE AGREEMENT (the
“Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose
address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ whose address
is _____________. 


WHEREAS:


The Purchaser desires to purchase
units (“Units”) of securities of the Company in accordance with the terms and conditions set forth herein.


The Company desires to issue and
sell Units to the Purchaser in accordance with the terms and conditions set forth herein.


THEREFORE, IT IS AGREED AS FOLLOWS


	 	1.	Units


 


Each Unit shall consist of one
(1) share of common stock of the Company and one (1) shares of the Series A Preferred Stock of the Company


	 	2.	Purchase Price


 


The purchase price per Unit (
“Purchase Price”), payable in US Dollars, shall be 5 cents per unit


	 	3.	Form of Payment


 


The Purchaser shall pay the Purchase
Price per Unit multiplied by that number of Units Purchased by wire transfer of immediately available funds to the Company


	WIRE INSTRUCTIONS:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 


 


	 	4.	Issuance of Units


 


5 business days subsequent to
receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Units purchased 


	 	5.	Purchaser’s Representations and Warranties


 


	 	(a)	As of the date hereof, the Purchaser is purchasing the Units for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended ( the “Act”). 


 


	 	(b)	The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the Act


 


	 	(c)	The Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Units which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to such disclosure to the Purchaser.


 


	 	(d)	Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.


 


	 	(e)	The execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser’s breach of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or by which Purchaser is or may be bound.


 


	 	6.	Company’s representations and warranties


 


	 	(a)	Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained. 


 


	 	(b)	The execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by which Company is or may be bound. 


  


	 	7.	Restricted Securities Acknowledgement


 


Purchaser acknowledges that any
securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act of 1933 shall constitute
“restricted securities” as that term is defined in Rule 144 promulgated under the Act , and shall contain the following
restrictive legend:


“THESE SECURITIES HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY NOT
BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH
LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED
TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”


	 	8.	Entire Agreement


 


This Agreement constitutes a final
written expression of all the terms of the Agreement between the parties regarding the subject matter hereof, are a complete and
exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings, and representations
between the parties.


	 	9.	Governing Law, Venue, Waiver Of Jury Trial


 


All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with
the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California for the adjudication of
any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. If either party
shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding.


IN WITNESS WHEREOF, the parties
have hereunto executed this Agreement on the 25th day of October, 2016.


	By:	 	 
	 	 	 
	Company	 	 
	 	 	 
	 	 	 
	 	 	 
	David Koos, CEO	 	 
	Regen Biopharma, Inc.	 	 
	 	 	 
	 	 	 
	Date:11/8/2016	 	 
	 	 	 
	Purchaser	 	 
	 	 	 
	 	 	 
	 	 	 
	By:	 	 
	Its:	 	 
	Date: 	 	 
	 	 	 
	Number of Units Purchased:	1000000	 	 
	Total Purchase Price:	$25000